Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Cancer - United States
doi 10.1002/cncr.30868
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Is Science as Global as We Think?

Trends in Ecology and Evolution
EvolutionEcologySystematicsBehavior
2005English

Is MRI as Safe as We Think?

South African Journal of Radiology
RadiologicalRadiologyNuclear MedicineUltrasound TechnologyImaging
2008English

Sometimes It Is Not as Much About How as It Is About Why

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2017English

Mount Fuji Is Not as “Active” as We Think

Indian Journal of Neurosurgery
2018English

Nivolumab Plus Carboplatin and Paclitaxel as the First-Line Therapy for Advanced Squamous Cell Carcinoma of the Lung With Strong Programmed Death-Ligand 1 Expression: A Case Report

Cureus
2019English

Is It Time for Quadruple Therapy to Be First Line?

Canadian Journal of Gastroenterology
2003English

The Mediterranean Diet: How Effective Is It as an Educational Tool?

Journal of Nutrition Education and Behavior
MedicineNutritionDietetics
2009English

What We Take Out of Ethylene Is as Important to You as What We Build Into It.

Chemical and Engineering News
Chemical Engineering
1970English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy